Seven of the 10 top selling drugs in 2014 will be products of biotechnology, according to a new report from EvaluatePharma, a London-based provider of information to the pharmaceutical and biotech industries. Roche’s (OTC:RHHBY), Avastin, a monoclonal antibody used to treat cancer, is expected to be the top seller, with revenues of more than $9.2 billion. Gone from the list will be many of today’s several small molecule drugs such as Lipitor, as patents expire.
Overall, EvaluatePharma said while the higher value products are shifting towards biotech, small-molecule drugs will continue to represent the bulk of the pharmaceutical industry’s sales in 2014, generating revenues of $406 billion compared to $169 billion for biotech products.
The report is available can be viewed at EvaluatePharma’s website.
Disclosure: No position